目的:采用Meta分析的方法探讨ERCC1rs11615多态性与卵巢癌铂类药物化疗敏感性的关系。
方法:发布,WebofScience,EMBASE,科克伦图书馆,中国国家知识基础设施(CNKI),到2020年9月,对中国万方数据库进行了全面搜索,以确定ERCC1rs11615多态性与卵巢癌化疗敏感性之间的关系。数据采用Stata15.0统计软件进行统计分析。
结果:共包括10篇已发表的论文,包括1866名卵巢癌患者。结果表明,ERCC1rs11615位点的等位基因C与等位基因T相比,合并OR为0.92(95CI:0.68~1.24,P>0.05)。在隐性、支配,纯合子,和杂合模型。根据种族的亚组分析,在亚洲人群中,所有基因型均有统计学意义.在等位基因中,支配,隐性,纯合和杂合模型,OR为0.70(95CI:0.51~0.95),0.20(95CI:0.07~0.56),0.79(95CI:0.63~1.00),0.21(95CI:0.07~0.59),0.19(95CI:0.07~0.54),分别,而在高加索人群中,未发现有统计学意义的基因型.
结论:ERCC1rs11615多态性与卵巢癌患者的化疗敏感性相关,尤其是在亚洲人口中,但不是在高加索人群中。
OBJECTIVE: To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis.
METHODS: Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software.
RESULTS: A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found.
CONCLUSIONS: The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.